-- John W. Smither Departing for Personal
Reasons
Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage
biopharmaceutical company, today announced the promotion of
Alexander Azoy to Chief Financial Officer (CFO). Mr. Azoy, who has
served as Sienna’s Corporate Controller since December 2017, will
succeed John W. Smither, who has resigned for personal reasons,
effective April 1, 2019.
“We are delighted to announce Alex’s promotion
to Chief Financial Officer,” said Frederick C. Beddingfield III,
M.D., Ph.D., President and Chief Executive Officer of Sienna. “His
expertise in both U.S. and international finance operations and
accounting, as well as corporate governance, particularly within
healthcare and life sciences, combined with his leadership within
the finance team has been invaluable. Alex is a laser-focused
professional, with a solid track record of developing and executing
financial objectives to achieve strategic priorities. When Alex
joined Sienna, we fully expected that in a very short time he would
be our succession plan for the CFO role. He is ready, and with his
experience and intimate knowledge of Sienna’s financial operations
he is the obvious choice. On behalf of our Board of Directors and
the entire Sienna team, I want to thank John for his remarkable
service to the Company and our shareholders and wish him all the
very best in his future personal and professional endeavors.”
Sienna also announced the appointment of Sean
Andrews to the Company’s leadership team as Vice President,
Investor Relations (IR). Mr. Andrews has served as Sienna’s Senior
Director, Investor Relations, since May 2017.
Dr. Beddingfield continued, “We are also glad to
announce Sean’s appointment to the leadership team as Vice
President, Investor Relations, to ensure continued access and
direct insight into Sienna’s strategy for the investor and analyst
community. His experience heading up IR spans two biotech initial
public offerings to a well-established, multi-billion dollar, fully
integrated pharmaceutical company. Sean has an impressive
relationship network and is very well regarded. He has been crucial
to our evolution as a company, helping us get in front of and
attract high quality investors and providing strong support as we
streamlined our focus on strategic priorities. We look forward to
continued leadership and valuable contributions from both Sean and
Alex, as we work together to build a strong presence in the
inflammation and immunology space and value for our
shareholders.”
Mr. Azoy has served as Sienna’s Corporate
Controller since December 2017. During that time, he has worked
directly with the Company’s CFO on financing projects and preparing
Sienna to be a public reporting company. Mr. Azoy was previously
the Vice President of Accounting for Smart & Final, a public
consumer products retailer with over $4 billion in annual revenues
and 12,000 employees, from January 2016 to November 2017. In this
role, he oversaw accounting operations, Sarbanes-Oxley compliance
and Securities and Exchange Commission (SEC) financial reporting.
Mr. Azoy was the Corporate Controller for Kythera
Biopharmaceuticals from March 2015 until December 2015, after it
was acquired by Allergan plc. At Kythera, he had responsibility for
accounting and tax functions, as well as SEC financial reporting
and preparing the company for its first commercial product launch.
From June 2013 to March 2015, Mr. Azoy served as Director, Finance
Business Strategy for Warner Bros. Entertainment, supporting
corporate finance initiatives and mergers and acquisitions. From
2003 to 2013, he held roles of increasing responsibility in Ernst
& Young’s audit practice, serving clients in the life sciences
sector, including Amgen. Mr. Azoy holds a bachelor’s degree in
accounting from California State University, Northridge. He is a
certified public accountant in California and a member of the
California Society of Certified Public Accountants.
Mr. Andrews has served as Sienna’s Senior
Director, Investor Relations, since May 2017. During that time, he
was instrumental to Sienna’s successful initial public offering
(IPO) and transition to being a public company, and was a strong
business partner to both the CEO and CFO regarding the Company’s IR
and corporate strategy, including messaging, investor targeting,
corporate financing, pipeline evaluation and business development.
Prior to joining Sienna, from January 2016 to April 2017, Mr.
Andrews served as Senior Director of Investor Relations at Novan,
Inc., where he was integral to its successful IPO and transition to
being a public company and chaired its disclosure committee. From
June 2013 through December 2015, Mr. Andrews was Managing Partner
of Credible Strategic Advisors, where he provided investor
relations and corporate strategy consulting services and assisted
sell-side equity research teams with company and asset valuations.
Previously, Mr. Andrews served in roles of increasing
responsibility at Medicis Pharmaceutical Corp., most recently as
Director, Investor Relations, from January 2008 until it was
acquired by Valeant in December 2012. Mr. Andrews is a United
States Air Force veteran, and holds undergraduate degrees in
aircraft systems maintenance technology and instructor of
technology and military science. He is a member of the National
Investor Relations Institute and the Public Relations Society of
America.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on bringing
unconventional scientific innovations to patients whose lives
remain burdened by their disease. We draw upon our deep knowledge
and experience in drug development across multiple therapeutic
areas as we build a unique, diversified, multi-asset portfolio of
therapies in immunology and inflammation that target select
pathways in specific tissues, with our initial focus on one of the
most important ‘immune’ tissues, the skin. We are leading the way
with our novel proprietary technology platform, applying a
scientific design process to create potent targeted
pharmacologically active molecules that are directed toward a
specific target tissue and a select disease pathway, and with
minimal to no systemic exposure. At Sienna, we are going where it
still matters for patients.
For more information, visit the Company’s
website at www.SiennaBio.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including but not limited to the statements by Sienna’s
Chief Executive Officer. Such forward-looking statements involve
substantial risks and uncertainties that could cause Sienna’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the pharmaceutical drug and medical device development processes,
including regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing
pharmaceutical drug and medical device products, Sienna’s ability
to raise sufficient capital to fund its development programs, and
other matters that could affect the sufficiency of existing cash to
fund operations and the availability or commercial potential of
Sienna’s drug candidates. Sienna undertakes no obligation to update
or revise any forward-looking statements. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the business of Sienna in general, see
Sienna’s most recent Annual Report on Form 10-K and any subsequent
current and periodic reports filed with the Securities and Exchange
Commission.
Contact:
MediaCaroline Van Hove cvanhove@siennabio.com
818-575-6250
InvestorsSean Andrews sandrews@siennabio.com
818-629-2244
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024